




Ten years later, this very idea becomes one of Europe’s largest biotech exits: US pharmaceutical giant Gilead acquires Munich biotech startup Tubulis for up to five billion US dollars. Munich Startup spoke with those who accompanied the journey. (Photo: AI-generated)



